-
1
-
-
0343492260
-
Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus
-
Rapp, U. R. et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl Acad. Sci. USA 80, 4218-4222 (1983). (Pubitemid 13077808)
-
(1983)
Proceedings of the National Academy of Sciences of the United States of America
, vol.80
, Issue.14
, pp. 4218-4222
-
-
Rapp, U.R.1
Goldsborough, M.D.2
Mark, G.E.3
-
2
-
-
0021341930
-
The human homologs of the raf(mil) oncogene are located on human chromosomes 3 and 4
-
Bonner, T. et al. The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4. Science 223, 71-74 (1984). (Pubitemid 14209914)
-
(1984)
Science
, vol.223
, Issue.4631
, pp. 71-74
-
-
Bonner, T.1
O'Brien, S.J.2
Nash, W.G.3
-
3
-
-
0021711728
-
Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins
-
DOI 10.1038/312558a0
-
Moelling, K., Heimann, B., Beimling, P., Rapp, U. R. & Sander, T. Serine-and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 312, 558-561 (1984). (Pubitemid 15182287)
-
(1984)
Nature
, vol.312
, Issue.5994
, pp. 558-561
-
-
Moelling, K.1
Heimann, B.2
Beimling, P.3
-
4
-
-
0022755881
-
Characterization of murine A-raf, a new oncogene related to the v-raf oncogene
-
Huleihel, M. et al. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol. Cell. Biol. 6, 2655-2662 (1986).
-
(1986)
Mol. Cell. Biol
, vol.6
, pp. 2655-2662
-
-
Huleihel, M.1
-
5
-
-
0023133794
-
The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus
-
Beck, T. W., Huleihel, M., Gunnell, M., Bonner, T. I. & Rapp, U. R. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res. 15, 595-609 (1987). (Pubitemid 17233996)
-
(1987)
Nucleic Acids Research
, vol.15
, Issue.2
, pp. 595-609
-
-
Beck, T.W.1
Huleihel, M.2
Gunnell, M.3
-
6
-
-
0024026952
-
B-raf, a new member of the raf family, is activated by DNA rearrangement
-
Ikawa, S. et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol. Cell. Biol. 8, 2651-2654 (1988).
-
(1988)
Mol. Cell. Biol
, vol.8
, pp. 2651-2654
-
-
Ikawa, S.1
-
7
-
-
0024119653
-
A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus
-
Marx, M. et al. A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus. EMBO J. 7, 3369-3373 (1988).
-
(1988)
EMBO J
, vol.7
, pp. 3369-3373
-
-
Marx, M.1
-
8
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
DOI 10.1038/nature00766
-
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). (Pubitemid 34716871)
-
(2002)
Nature
, vol.417
, Issue.6892
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
Davis, N.11
Dicks, E.12
Ewing, R.13
Floyd, Y.14
Gray, K.15
Hall, S.16
Hawes, R.17
Hughes, J.18
Kosmidou, V.19
Menzies, A.20
Mould, C.21
Parker, A.22
Stevens, C.23
Watt, S.24
Hooper, S.25
Wilson, R.26
Jayatilake, H.27
Gusterson, B.A.28
Cooper, C.29
Shipley, J.30
Hargrave, D.31
Pritchard-Jones, K.32
Maitland, N.33
Chenevix-Trench, G.34
Riggins, G.J.35
Bigner, D.D.36
Palmleri, G.37
Cossu, A.38
Flanagan, A.39
Nicholson, A.40
Ho, J.W.C.41
Leung, S.Y.42
Yuen, S.T.43
Weber, B.L.44
Seigler, H.F.45
Darrow, T.L.46
Paterson, H.47
Marais, R.48
Marshall, C.J.49
Wooster, R.50
Stratton, M.R.51
Futreal, P.A.52
more..
-
9
-
-
0036654443
-
A genome-based strategy uncovers frequent BRAF mutations in melanoma
-
DOI 10.1016/S1535-6108(02)00089-2
-
Pollock, P. M. & Meltzer, P. S. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2, 5-7 (2002). (Pubitemid 41043982)
-
(2002)
Cancer Cell
, vol.2
, Issue.1
, pp. 5-7
-
-
Pollock, P.M.1
Meltzer, P.S.2
-
10
-
-
0037194728
-
RAF/RAS oncogenes and mismatch-repair status
-
DOI 10.1038/418934a
-
Rajagopalan, H. et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934 (2002). (Pubitemid 34976022)
-
(2002)
Nature
, vol.418
, Issue.6901
, pp. 934
-
-
Rajagopalan, H.1
Bardelli, A.2
Lengauer, C.3
Kinzler, K.W.4
Vogelstein, B.5
Velculescu, V.E.6
-
11
-
-
0038664387
-
BRAF mutation in papillary thyroid carcinoma
-
Cohen, Y. et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst. 95, 625-627 (2003). (Pubitemid 36553510)
-
(2003)
Journal of the National Cancer Institute
, vol.95
, Issue.8
, pp. 625-627
-
-
Cohen, Y.1
Xing, M.2
Mambo, E.3
Gou, Z.4
Wu, G.5
Trink, B.6
Beller, U.7
Westra, W.H.8
Ladenson, P.W.9
Sidransky, D.10
-
12
-
-
0142135475
-
BRAF mutations in papillary carcinomas of the thyroid
-
DOI 10.1038/sj.onc.1206739
-
Fukushima, T. et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22, 6455-6457 (2003). (Pubitemid 37281692)
-
(2003)
Oncogene
, vol.22
, Issue.41
, pp. 6455-6457
-
-
Fukushima, T.1
Suzuki, S.2
Mashiko, M.3
Ohtake, T.4
Endo, Y.5
Takebayashi, Y.6
Sekikawa, K.7
Hagiwara, K.8
Takenoshita, S.9
-
13
-
-
0037379904
-
High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
-
Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457 (2003). (Pubitemid 36373628)
-
(2003)
Cancer Research
, vol.63
, Issue.7
, pp. 1454-1457
-
-
Kimura, E.T.1
Nikiforova, M.N.2
Zhu, Z.3
Knauf, J.A.4
Nikiforov, Y.E.5
Fagin, J.A.6
-
14
-
-
0041589377
-
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
-
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B. & Prinz, R. A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63, 4561-4567 (2003). (Pubitemid 36951030)
-
(2003)
Cancer Research
, vol.63
, Issue.15
, pp. 4561-4567
-
-
Xu, X.1
Quiros, R.M.2
Gattuso, P.3
Ain, K.B.4
Prinz, R.A.5
-
15
-
-
10744222003
-
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
-
DOI 10.1210/jc.2003-030838
-
Nikiforova, M. N. et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404 (2003). (Pubitemid 37452745)
-
(2003)
Journal of Clinical Endocrinology and Metabolism
, vol.88
, Issue.11
, pp. 5399-5404
-
-
Nikiforova, M.N.1
Kimura, E.T.2
Gandhi, M.3
Biddinger, P.W.4
Knauf, J.A.5
Basolo, F.6
Zhu, Z.7
Giannini, R.8
Salvatore, G.9
Fusco, A.10
Santoro, M.11
Fagin, J.A.12
Nikiforov, Y.E.13
-
16
-
-
0037454224
-
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
-
Singer, G. et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst. 95, 484-486 (2003). (Pubitemid 36432423)
-
(2003)
Journal of the National Cancer Institute
, vol.95
, Issue.6
, pp. 484-486
-
-
Singer, G.1
Oldt III, R.2
Cohen, Y.3
Wang, B.G.4
Sidransky, D.5
Kurman, R.J.6
Shih, I.-M.7
-
17
-
-
0036894746
-
BRAF and RAS mutations in human lung cancer and melanoma
-
Brose, M. S. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997-7000 (2002). (Pubitemid 35424092)
-
(2002)
Cancer Research
, vol.62
, Issue.23
, pp. 6997-7000
-
-
Brose, M.S.1
Volpe, P.2
Feldman, M.3
Kumar, M.4
Rishi, I.5
Gerrero, R.6
Einhorn, E.7
Herlyn, M.8
Minna, J.9
Nicholson, A.10
Roth, J.A.11
Albelda, S.M.12
Davies, H.13
Cox, C.14
Brignell, G.15
Stephens, P.16
Andrew Futreal, P.17
Wooster, R.18
Stratton, M.R.19
Weber, B.L.20
more..
-
18
-
-
0242574321
-
BRAF and KRAS mutations in stomach cancer
-
DOI 10.1038/sj.onc.1206749
-
Lee, S. H. et al. BRAF and KRAS mutations in stomach cancer. Oncogene 22, 6942-6945 (2003). (Pubitemid 37386695)
-
(2003)
Oncogene
, vol.22
, Issue.44
, pp. 6942-6945
-
-
Lee, S.H.1
Lee, J.W.2
Soung, Y.H.3
Kim, H.S.4
Park, W.S.5
Kim, S.Y.6
Lee, J.H.7
Park, J.Y.8
Cho, Y.G.9
Kim, C.J.10
Nam, S.W.11
Kim, S.H.12
Lee, J.Y.13
Yoo, N.J.14
-
19
-
-
0037624602
-
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
-
DOI 10.1136/gut.52.5.706
-
Tannapfel, A. et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52, 706-712 (2003). (Pubitemid 36528874)
-
(2003)
Gut
, vol.52
, Issue.5
, pp. 706-712
-
-
Tannapfel, A.1
Sommerer, F.2
Benicke, M.3
Katalinic, A.4
Uhlmann, D.5
Witzigmann, H.6
Hauss, J.7
Wittekind, C.8
-
20
-
-
10744233317
-
Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma
-
DOI 10.1038/sj.onc.1207189
-
Sommerer, F. et al. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 23, 554-558 (2004). (Pubitemid 38175010)
-
(2004)
Oncogene
, vol.23
, Issue.2
, pp. 554-558
-
-
Sommerer, F.1
Vieth, M.2
Markwarth, A.3
Rohrich, K.4
Vomschloss, S.5
May, A.6
Ell, C.7
Stolte, M.8
Hengge, U.R.9
Wittekind, C.10
Tannapfel, A.11
-
21
-
-
0043091970
-
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck
-
DOI 10.1038/sj.onc.1206705
-
Weber, A. et al. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22, 4757-4759 (2003). (Pubitemid 36976451)
-
(2003)
Oncogene
, vol.22
, Issue.30
, pp. 4757-4759
-
-
Weber, A.1
Langhanki, L.2
Sommerer, F.3
Markwarth, A.4
Wittekind, C.5
Tannapfel, A.6
-
22
-
-
84856845687
-
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy
-
Colombino, M. et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 3, e259 (2012).
-
(2012)
Cell Death Dis
, vol.3
-
-
Colombino, M.1
-
23
-
-
77956904045
-
Recurrent BRAF mutations in Langerhans cell histiocytosis
-
Badalian-Very, G. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116, 1919-1923 (2010).
-
(2010)
Blood
, vol.116
, pp. 1919-1923
-
-
Badalian-Very, G.1
-
24
-
-
50249152932
-
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
-
Agaram, N. P. et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47, 853-859 (2008).
-
(2008)
Genes Chromosomes Cancer
, vol.47
, pp. 853-859
-
-
Agaram, N.P.1
-
25
-
-
79951494668
-
Initial genome sequencing and analysis of multiple myeloma
-
Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
-
(2011)
Nature
, vol.471
, pp. 467-472
-
-
Chapman, M.A.1
-
26
-
-
55349107544
-
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas
-
Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673-8677 (2008).
-
(2008)
Cancer Res
, vol.68
, pp. 8673-8677
-
-
Jones, D.T.1
-
27
-
-
43049124130
-
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
-
DOI 10.1172/JCI33656
-
Pfister, S. et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 118, 1739-1749 (2008). (Pubitemid 351632377)
-
(2008)
Journal of Clinical Investigation
, vol.118
, Issue.5
, pp. 1739-1749
-
-
Pfister, S.1
Janzarik, W.G.2
Remke, M.3
Ernst, A.4
Werft, W.5
Becker, N.6
Toedt, G.7
Wittmann, A.8
Kratz, C.9
Olbrich, H.10
Ahmadi, R.11
Thieme, B.12
Joos, S.13
Radlwimmer, B.14
Kulozik, A.15
Pietsch, T.16
Herold-Mende, C.17
Gnekow, A.18
Reifenberger, G.19
Korshunov, A.20
Scheurlen, W.21
Omran, H.22
Lichter, P.23
more..
-
28
-
-
66949147222
-
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene
-
Sievert, A. J. et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 19, 449-458 (2009).
-
(2009)
Brain Pathol
, vol.19
, pp. 449-458
-
-
Sievert, A.J.1
-
29
-
-
79953184268
-
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications
-
Dias-Santagata, D. et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS ONE 6, e17948 (2011).
-
(2011)
PLoS ONE
, vol.6
-
-
Dias-Santagata, D.1
-
30
-
-
79954441895
-
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
-
Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397-405 (2011).
-
(2011)
Acta Neuropathol
, vol.121
, pp. 397-405
-
-
Schindler, G.1
-
31
-
-
79959293462
-
BRAF mutations in hairy-cell leukemia
-
Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 2305-2315
-
-
Tiacci, E.1
-
32
-
-
0037228055
-
High frequency of BRAF mutations in nevi
-
DOI 10.1038/ng1054
-
Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19-20 (2003). (Pubitemid 36068675)
-
(2003)
Nature Genetics
, vol.33
, Issue.1
, pp. 19-20
-
-
Pollock, P.M.1
Harper, U.L.2
Hansen, K.S.3
Yudt, L.M.4
Stark, M.5
Robbins, C.M.6
Moses, T.Y.7
Hostetter, G.8
Wagner, U.9
Kakareka, J.10
Salem, G.11
Pohida, T.12
Heenan, P.13
Duray, P.14
Kallioniemi, O.15
Hayward, N.K.16
Trent, J.M.17
Meltzer, P.S.18
-
33
-
-
23244447037
-
E600-associated senescence-like cell cycle arrest of human naevi
-
DOI 10.1038/nature03890
-
Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005). (Pubitemid 41117276)
-
(2005)
Nature
, vol.436
, Issue.7051
, pp. 720-724
-
-
Michaloglou, C.1
Vredeveld, L.C.W.2
Soengas, M.S.3
Denoyelle, C.4
Kuilman, T.5
Van Der Horst, C.M.A.M.6
Majoor, D.M.7
Shay, J.W.8
Mooi, W.J.9
Peeper, D.S.10
-
34
-
-
0037442752
-
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation
-
Satyamoorthy, K. et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63, 756-759 (2003). (Pubitemid 36231971)
-
(2003)
Cancer Research
, vol.63
, Issue.4
, pp. 756-759
-
-
Satyamoorthy, K.1
Li, G.2
Gerrero, M.R.3
Brose, M.S.4
Volpe, P.5
Weber, B.L.6
Van Belle, P.7
Elder, D.E.8
Herlyn, M.9
-
35
-
-
0042885906
-
BRAF as a potential therapeutic target in melanoma and other malignancies
-
DOI 10.1016/S1535-6108(03)00189-2
-
Tuveson, D. A., Weber, B. L. & Herlyn, M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 95-98 (2003). (Pubitemid 37040825)
-
(2003)
Cancer Cell
, vol.4
, Issue.2
, pp. 95-98
-
-
Tuveson, D.A.1
Weber, B.L.2
Herlyn, M.3
-
36
-
-
4344584872
-
B-RAF is a therapeutic target in melanoma
-
DOI 10.1038/sj.onc.1207785
-
Karasarides, M. et al. B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004). (Pubitemid 39215299)
-
(2004)
Oncogene
, vol.23
, Issue.37
, pp. 6292-6298
-
-
Karasarides, M.1
Chiloeches, A.2
Hayward, R.3
Niculescu-Duvaz, D.4
Scanlon, I.5
Friedlos, F.6
Ogilvie, L.7
Hedley, D.8
Martin, J.9
Marshall, C.J.10
Springer, C.J.11
Marais, R.12
-
37
-
-
1942506706
-
V599EB-RAF is an oncogene in melanocytes
-
Wellbrock, C. et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342 (2004).
-
(2004)
Cancer Res
, vol.64
, pp. 2338-2342
-
-
Wellbrock, C.1
-
38
-
-
0141816881
-
V599E in human melanoma abrogates transformation
-
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M. & Tuveson, D. A. Suppression of BRAFV599E in human melanoma abrogates transformation. Cancer Res. 63, 5198-5202 (2003). (Pubitemid 37139827)
-
(2003)
Cancer Research
, vol.63
, Issue.17
, pp. 5198-5202
-
-
Hingorani, S.R.1
Jacobetz, M.A.2
Robertson, G.P.3
Herlyn, M.4
Tuveson, D.A.5
-
39
-
-
31544442670
-
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
-
DOI 10.1158/0008-5472.CAN-05-2720
-
Hoeflich, K. P. et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66, 999-1006 (2006). (Pubitemid 43165968)
-
(2006)
Cancer Research
, vol.66
, Issue.2
, pp. 999-1006
-
-
Hoeflich, K.P.1
Gray, D.C.2
Eby, M.T.3
Tien, J.Y.4
Wong, L.5
Bower, J.6
Gogineni, A.7
Zha, J.8
Cole, M.J.9
Stern, H.M.10
Murray, L.J.11
Davis, D.P.12
Seshagiri, S.13
-
40
-
-
33847201454
-
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors
-
Dankort, D. et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379-384 (2007).
-
(2007)
Genes Dev
, vol.21
, pp. 379-384
-
-
Dankort, D.1
-
41
-
-
58049220349
-
BRAF activation initiates but does not maintain invasive prostate adenocarcinoma
-
Jeong, J. H. et al. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS ONE 3, e3949 (2008).
-
(2008)
PLoS ONE
, vol.3
-
-
Jeong, J.H.1
-
42
-
-
65649147543
-
BrafV600E cooperates with Pten loss to induce metastatic melanoma
-
Dankort, D. et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genet. 41, 544-552 (2009).
-
(2009)
Nature Genet
, vol.41
, pp. 544-552
-
-
Dankort, D.1
-
43
-
-
67349212438
-
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
-
Goel, V. K. et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28, 2289-2298 (2009).
-
(2009)
Oncogene
, vol.28
, pp. 2289-2298
-
-
Goel, V.K.1
-
44
-
-
84055191090
-
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
-
Chakravarty, D. et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700-4711 (2011).
-
(2011)
J. Clin. Invest
, vol.121
, pp. 4700-4711
-
-
Chakravarty, D.1
-
45
-
-
79957909599
-
Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse
-
Charles, R. P., Iezza, G., Amendola, E., Dankort, D. & McMahon, M. Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse. Cancer Res. 71, 3863-3871 (2011).
-
(2011)
Cancer Res
, vol.71
, pp. 3863-3871
-
-
Charles, R.P.1
Iezza, G.2
Amendola, E.3
Dankort, D.4
McMahon, M.5
-
46
-
-
1642556736
-
Raf pathway inhibitors in oncology
-
Bollag, G., Freeman, S., Lyons, J. F. & Post, L. E. Raf pathway inhibitors in oncology. Curr. Opin. Investig. Drugs 4, 1436-1441 (2003). (Pubitemid 38111205)
-
(2003)
Current Opinion in Investigational Drugs
, vol.4
, Issue.12
, pp. 1436-1441
-
-
Bollag, G.1
Freeman, S.2
Lyons, J.F.3
Post, L.E.4
-
47
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004). (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
48
-
-
33846260566
-
Sorafenib for the treatment of advanced renal cell carcinoma
-
DOI 10.1158/1078-0432.CCR-06-1249
-
Kane, R. C. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271-7278 (2006). (Pubitemid 46095398)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.24
, pp. 7271-7278
-
-
Kane, R.C.1
Farrell, A.T.2
Saber, H.3
Tang, S.4
Williams, G.5
Jee, J.M.6
Liang, C.7
Booth, B.8
Chidambaram, N.9
Morse, D.10
Sridhara, R.11
Garvey, P.12
Justice, R.13
Pazdur, R.14
-
49
-
-
61449175950
-
Sorafenib for the treatment of unresectable hepatocellular carcinoma
-
Kane, R. C. et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14, 95-100 (2009).
-
(2009)
Oncologist
, vol.14
, pp. 95-100
-
-
Kane, R.C.1
-
50
-
-
33749238553
-
Discovery and development of sorafenib: A multikinase inhibitor for treating cancer
-
DOI 10.1038/nrd2130, PII NRD2130
-
Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov. 5, 835-844 (2006). (Pubitemid 44480537)
-
(2006)
Nature Reviews Drug Discovery
, vol.5
, Issue.10
, pp. 835-844
-
-
Wilhelm, S.1
Carter, C.2
Lynch, M.3
Lowinger, T.4
Dumas, J.5
Smith, R.A.6
Schwartz, B.7
Simantov, R.8
Kelley, S.9
-
51
-
-
51049095131
-
A phase i trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
-
Flaherty, K. T. et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14, 4836-4842 (2008).
-
(2008)
Clin. Cancer Res
, vol.14
, pp. 4836-4842
-
-
Flaherty, K.T.1
-
52
-
-
67649909568
-
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
-
Hauschild, A. et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830 (2009).
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 2823-2830
-
-
Hauschild, A.1
-
53
-
-
78650824497
-
A phase II trial of sorafenib in metastatic melanoma with tissue correlates
-
Ott, P. A. et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 5, e15588 (2010).
-
(2010)
PLoS ONE
, vol.5
-
-
Ott, P.A.1
-
54
-
-
12144289677
-
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
-
DOI 10.1016/S0092-8674(04)00215-6, PII S0092867404002156
-
Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004). (Pubitemid 38410730)
-
(2004)
Cell
, vol.116
, Issue.6
, pp. 855-867
-
-
Wan, P.T.C.1
Garnett, M.J.2
Roe, S.M.3
Lee, S.4
Niculescu-Duvaz, D.5
Good, V.M.6
Project, C.G.7
Jones, C.M.8
Marshall, C.J.9
Springer, C.J.10
Barford, D.11
Marais, R.12
-
55
-
-
84868193136
-
Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma
-
16 Jul doi:10.1111/j.1365-2133.2012.11155.x
-
Anforth, R. M. et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 16 Jul 2012 (doi:10.1111/j.1365-2133.2012.11155.x).
-
(2012)
Br. J. Dermatol.
-
-
Anforth, R.M.1
-
56
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial
-
Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901 (2012).
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
-
57
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
-
58
-
-
84859873585
-
RAF265 inhibits the growth of advanced human melanoma tumors
-
Su, Y. et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res. 18, 2184-2198 (2012).
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 2184-2198
-
-
Su, Y.1
-
59
-
-
84862735870
-
CEP-32496: A novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity
-
James, J. et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol. Cancer Ther. 11, 930-941 (2012).
-
(2012)
Mol. Cancer Ther
, vol.11
, pp. 930-941
-
-
James, J.1
-
60
-
-
57749188299
-
Targeting cancer with small molecule kinase inhibitors
-
Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Rev. Cancer 9, 28-39 (2009).
-
(2009)
Nature Rev. Cancer
, vol.9
, pp. 28-39
-
-
Zhang, J.1
Yang, P.L.2
Gray, N.S.3
-
61
-
-
80555156183
-
Targeting cancer with small-molecular-weight kinase inhibitors
-
Fabbro, D., Cowan-Jacob, S. W., Mobitz, H. & Martiny-Baron, G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol. Biol. 795, 1-34 (2012).
-
(2012)
Methods Mol. Biol
, vol.795
, pp. 1-34
-
-
Fabbro, D.1
Cowan-Jacob, S.W.2
Mobitz, H.3
Martiny-Baron, G.4
-
62
-
-
42949149240
-
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
-
DOI 10.1073/pnas.0711741105
-
Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008). (Pubitemid 351723664)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.8
, pp. 3041-3046
-
-
Tsai, J.1
Lee, J.T.2
Wang, W.3
Zhang, J.4
Cho, H.5
Mamo, S.6
Bremer, R.7
Gillette, S.8
Kong, J.9
Haass, N.K.10
Sproesser, K.11
Li, L.12
Smalley, K.S.M.13
Fong, D.14
Zhu, Y.-L.15
Marimuthu, A.16
Nguyen, H.17
Lam, B.18
Liu, J.19
Cheung, I.20
Rice, J.21
Suzuki, Y.22
Luu, C.23
Settachatgul, C.24
Shellooe, R.25
Cantwell, J.26
Kim, S.-H.27
Schlessinger, J.28
Zhang, K.Y.J.29
West, B.L.30
Powell, B.31
Habets, G.32
Zhang, C.33
Ibrahim, P.N.34
Hirth, P.35
Artis, D.R.36
Herlyn, M.37
Bollag, G.38
more..
-
63
-
-
75849142553
-
Scaffold-based design of kinase inhibitors for cancer therapy
-
Zhang, C. & Bollag, G. Scaffold-based design of kinase inhibitors for cancer therapy. Curr. Opin. Genet. Dev. 20, 79-86 (2010).
-
(2010)
Curr. Opin. Genet. Dev
, vol.20
, pp. 79-86
-
-
Zhang, C.1
Bollag, G.2
-
64
-
-
12344318177
-
Fragment-based lead discovery using X-ray crystallography
-
DOI 10.1021/jm0495778
-
Hartshorn, M. J. et al. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 48, 403-413 (2005). (Pubitemid 40139783)
-
(2005)
Journal of Medicinal Chemistry
, vol.48
, Issue.2
, pp. 403-413
-
-
Hartshorn, M.J.1
Murray, C.W.2
Cleasby, A.3
Frederickson, M.4
Tickle, I.J.5
Jhoti, H.6
-
65
-
-
67849113794
-
The rise of fragment-based drug discovery
-
Murray, C. W. & Rees, D. C. The rise of fragment-based drug discovery. Nature Chem. 1, 187-192 (2009).
-
(2009)
Nature Chem
, vol.1
, pp. 187-192
-
-
Murray, C.W.1
Rees, D.C.2
-
66
-
-
84860524795
-
Structural approaches to obtain kinase selectivity
-
Norman, R. A., Toader, D. & Ferguson, A. D. Structural approaches to obtain kinase selectivity. Trends Pharmacol. Sci. 33, 273-278 (2012).
-
(2012)
Trends Pharmacol. Sci
, vol.33
, pp. 273-278
-
-
Norman, R.A.1
Toader, D.2
Ferguson, A.D.3
-
67
-
-
16244377514
-
Crystal structures of proto-oncogene kinase Pim1: A target of aberrant somatic hypermutations in diffuse large cell lymphoma
-
DOI 10.1016/j.jmb.2005.02.039
-
Kumar, A. et al. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J. Mol. Biol. 348, 183-193 (2005). (Pubitemid 40461849)
-
(2005)
Journal of Molecular Biology
, vol.348
, Issue.1
, pp. 183-193
-
-
Kumar, A.1
Mandiyan, V.2
Suzuki, Y.3
Zhang, C.4
Rice, J.5
Tsai, J.6
Artis, D.R.7
Ibrahim, P.8
Bremer, R.9
-
68
-
-
20844437061
-
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design
-
DOI 10.1038/nbt1059
-
Card, G. L. et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nature Biotech. 23, 201-207 (2005). (Pubitemid 40255330)
-
(2005)
Nature Biotechnology
, vol.23
, Issue.2
, pp. 201-207
-
-
Card, G.L.1
Blasdel, L.2
England, B.P.3
Zhang, C.4
Suzuki, Y.5
Gillette, S.6
Fong, D.7
Ibrahim, P.N.8
Artis, D.R.9
Bollag, G.10
Milburn, M.V.11
Kim, S.-H.12
Schlessinger, J.13
Zhang, K.Y.J.14
-
69
-
-
58549087807
-
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
-
Artis, D. R. et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. Natl Acad. Sci. USA 106, 262-267 (2009).
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, pp. 262-267
-
-
Artis, D.R.1
-
70
-
-
77956513286
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
-
Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
-
(2010)
Nature
, vol.467
, pp. 596-599
-
-
Bollag, G.1
-
71
-
-
31144453233
-
BRAF mutation predicts sensitivity to MEK inhibition
-
DOI 10.1038/nature04304, PII NATURE04304
-
Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006). (Pubitemid 43128863)
-
(2006)
Nature
, vol.439
, Issue.7074
, pp. 358-362
-
-
Solit, D.B.1
Garraway, L.A.2
Pratilas, C.A.3
Sawai, A.4
Getz, G.5
Basso, A.6
Ye, Q.7
Lobo, J.M.8
She, Y.9
Osman, I.10
Golub, T.R.11
Sebolt-Leopold, J.12
Sellers, W.R.13
Rosen, N.14
-
72
-
-
77949354563
-
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells
-
Halaban, R. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190-200 (2010).
-
(2010)
Pigment Cell Melanoma Res
, vol.23
, pp. 190-200
-
-
Halaban, R.1
-
73
-
-
77957089182
-
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
-
Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903-14908 (2010).
-
(2010)
Proc. Natl Acad. Sci. USA
, vol.107
, pp. 14903-14908
-
-
Joseph, E.W.1
-
74
-
-
77957968556
-
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
-
Lee, J. T. et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827 (2010).
-
(2010)
Pigment Cell Melanoma Res
, vol.23
, pp. 820-827
-
-
Lee, J.T.1
-
75
-
-
77954235111
-
Targeting the mitogen-activated protein kinase pathway: Physiological feedback and drug response
-
Pratilas, C. A. & Solit, D. B. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin. Cancer Res. 16, 3329-3334 (2010).
-
(2010)
Clin. Cancer Res
, vol.16
, pp. 3329-3334
-
-
Pratilas, C.A.1
Solit, D.B.2
-
76
-
-
77950954465
-
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
-
Sondergaard, J. N. et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J. Transl. Med. 8, 39 (2010).
-
(2010)
J. Transl. Med
, vol.8
, pp. 39
-
-
Sondergaard, J.N.1
-
77
-
-
77956029013
-
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma
-
Tap, W. D. et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12, 637-649 (2010).
-
(2010)
Neoplasia
, vol.12
, pp. 637-649
-
-
Tap, W.D.1
-
78
-
-
77954376912
-
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
-
Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
-
(2010)
Cancer Res
, vol.70
, pp. 5518-5527
-
-
Yang, H.1
-
79
-
-
47249097988
-
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
-
Sala, E. et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6, 751-759 (2008).
-
(2008)
Mol. Cancer Res
, vol.6
, pp. 751-759
-
-
Sala, E.1
-
80
-
-
75149188152
-
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells
-
Salerno, P. et al. Cytostatic activity of adenosine triphosphate- competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 95, 450-455 (2010).
-
(2010)
J. Clin. Endocrinol. Metab
, vol.95
, pp. 450-455
-
-
Salerno, P.1
-
81
-
-
77953276524
-
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
-
Paraiso, K. H. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730 (2010).
-
(2010)
Br. J. Cancer
, vol.102
, pp. 1724-1730
-
-
Paraiso, K.H.1
-
82
-
-
77955757007
-
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells
-
Shao, Y. & Aplin, A. E. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670-6681 (2010).
-
(2010)
Cancer Res
, vol.70
, pp. 6670-6681
-
-
Shao, Y.1
Aplin, A.E.2
-
83
-
-
84861381332
-
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
-
Basile, K. J., Abel, E. V. & Aplin, A. E. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31, 2471-2479 (2011).
-
(2011)
Oncogene
, vol.31
, pp. 2471-2479
-
-
Basile, K.J.1
Abel, E.V.2
Aplin, A.E.3
-
84
-
-
84862778070
-
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
-
Deng, W. et al. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 25, 248-258 (2012).
-
(2012)
Pigment Cell Melanoma Res
, vol.25
, pp. 248-258
-
-
Deng, W.1
-
85
-
-
78751648455
-
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
-
Kaplan, F. M., Shao, Y., Mayberry, M. M. & Aplin, A. E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 30, 366-371 (2011).
-
(2011)
Oncogene
, vol.30
, pp. 366-371
-
-
Kaplan, F.M.1
Shao, Y.2
Mayberry, M.M.3
Aplin, A.E.4
-
86
-
-
84856217925
-
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
-
Xing, F. et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene 31, 446-457 (2012).
-
(2012)
Oncogene
, vol.31
, pp. 446-457
-
-
Xing, F.1
-
87
-
-
29144462587
-
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
-
DOI 10.1016/j.molcel.2005.10.022, PII S109727650501717X
-
Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969 (2005). (Pubitemid 41814884)
-
(2005)
Molecular Cell
, vol.20
, Issue.6
, pp. 963-969
-
-
Garnett, M.J.1
Rana, S.2
Paterson, H.3
Barford, D.4
Marais, R.5
-
88
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
-
89
-
-
84863012433
-
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
-
Yang, H. et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 72, 779-789 (2012).
-
(2012)
Cancer Res
, vol.72
, pp. 779-789
-
-
Yang, H.1
-
90
-
-
70349438995
-
A dimerization-dependent mechanism drives RAF catalytic activation
-
Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
-
(2009)
Nature
, vol.461
, pp. 542-545
-
-
Rajakulendran, T.1
Sahmi, M.2
Lefrancois, M.3
Sicheri, F.4
Therrien, M.5
-
91
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
92
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
-
(2010)
N. Engl. J. Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
-
93
-
-
78649723255
-
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors
-
Abstract 3534
-
Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28, Abstract 3534 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
-
-
Kopetz, S.1
-
94
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman, J. A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
-
95
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
-
96
-
-
84863746052
-
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
-
McArthur, G. A. et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J. Clin. Oncol. 30, 1628-1634 (2012).
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 1628-1634
-
-
McArthur, G.A.1
-
97
-
-
79951818357
-
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
-
Jiang, C. C. et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 1, e69 (2010).
-
(2010)
Cell Death Dis
, vol.1
-
-
Jiang, C.C.1
-
98
-
-
84055212088
-
Targeted therapy for BRAFV600E malignant astrocytoma
-
Nicolaides, T. P. et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595-7604 (2011).
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 7595-7604
-
-
Nicolaides, T.P.1
-
99
-
-
62849094740
-
Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAFV600E
-
Esteve-Puig, R., Canals, F., Colome, N., Merlino, G. & Recio, J. A. Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAFV600E. PLoS ONE 4, e4771 (2009).
-
(2009)
PLoS ONE
, vol.4
-
-
Esteve-Puig, R.1
Canals, F.2
Colome, N.3
Merlino, G.4
Recio, J.A.5
-
100
-
-
79956260998
-
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
-
Niehr, F. et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J. Transl. Med. 9, 76 (2011).
-
(2011)
J. Transl. Med
, vol.9
, pp. 76
-
-
Niehr, F.1
-
101
-
-
79953064886
-
DHODH modulates transcriptional elongation in the neural crest and melanoma
-
White, R. M. et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518-522 (2011).
-
(2011)
Nature
, vol.471
, pp. 518-522
-
-
White, R.M.1
-
102
-
-
79953325104
-
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
-
Paraiso, K. H. et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760 (2011).
-
(2011)
Cancer Res
, vol.71
, pp. 2750-2760
-
-
Paraiso, K.H.1
-
103
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
-
104
-
-
84861863158
-
EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran, R. B. et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
-
(2012)
Cancer Discov
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
-
105
-
-
49649118852
-
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
-
Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
-
(2008)
Cancer Res
, vol.68
, pp. 4853-4861
-
-
Montagut, C.1
-
106
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
-
(2010)
Nature
, vol.468
, pp. 973-977
-
-
Nazarian, R.1
-
107
-
-
78650008177
-
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
-
Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
-
(2010)
Cancer Cell
, vol.18
, pp. 683-695
-
-
Villanueva, J.1
-
108
-
-
84859183431
-
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
-
Shi, H. et al. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3, 724 (2012).
-
(2012)
Nature Commun
, vol.3
, pp. 724
-
-
Shi, H.1
-
109
-
-
79953240219
-
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells
-
Little, A. S. et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 4, ra17 (2011).
-
(2011)
Sci. Signal
, vol.4
-
-
Little, A.S.1
-
110
-
-
78649436372
-
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
-
Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010).
-
(2010)
Sci. Signal
, vol.3
-
-
Corcoran, R.B.1
-
111
-
-
84864285794
-
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
-
Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
-
(2012)
Nature
, vol.487
, pp. 500-504
-
-
Straussman, R.1
-
112
-
-
84864286442
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
-
Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
-
(2012)
Nature
, vol.487
, pp. 505-509
-
-
Wilson, T.R.1
-
113
-
-
79951961755
-
Resistance to BRAF inhibition in melanomas
-
Solit, D. B. & Rosen, N. Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364, 772-774 (2011).
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 772-774
-
-
Solit, D.B.1
Rosen, N.2
-
114
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
-
(2011)
Nature
, vol.480
, pp. 387-390
-
-
Poulikakos, P.I.1
-
115
-
-
0033179479
-
Paradoxical activation of Raf by a novel Raf inhibitor
-
DOI 10.1016/S1074-5521(99)80088-X
-
Hall-Jackson, C. A. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568 (1999). (Pubitemid 29380770)
-
(1999)
Chemistry and Biology
, vol.6
, Issue.8
, pp. 559-568
-
-
Hall-Jackson, C.A.1
Eyers, P.A.2
Cohen, P.3
Goedert, M.4
Boyle, F.T.5
Hewitt, N.6
Plant, H.7
Hedge, P.8
-
116
-
-
33845292259
-
A negative feedback signaling network underlies oncogene-induced senescence
-
DOI 10.1016/j.ccr.2006.10.003, PII S1535610806002893
-
Courtois-Cox, S. et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459-472 (2006). (Pubitemid 44872980)
-
(2006)
Cancer Cell
, vol.10
, Issue.6
, pp. 459-472
-
-
Courtois-Cox, S.1
Genther Williams, S.M.2
Reczek, E.E.3
Johnson, B.W.4
McGillicuddy, L.T.5
Johannessen, C.M.6
Hollstein, P.E.7
MacCollin, M.8
Cichowski, K.9
-
117
-
-
19944430124
-
Regulation of Raf-1 by direct feedback phosphorylation
-
DOI 10.1016/j.molcel.2004.11.055, PII S1097276504008019
-
Dougherty, M. K. et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224 (2005). (Pubitemid 40138617)
-
(2005)
Molecular Cell
, vol.17
, Issue.2
, pp. 215-224
-
-
Dougherty, M.K.1
Muller, J.2
Ritt, D.A.3
Zhou, M.4
Zhou, X.Z.5
Copeland, T.D.6
Conrads, T.P.7
Veenstra, T.D.8
Lu, K.P.9
Morrison, D.K.10
-
118
-
-
75149117479
-
Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling
-
Ritt, D. A., Monson, D. M., Specht, S. I. & Morrison, D. K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 30, 806-819 (2010).
-
(2010)
Mol. Cell. Biol
, vol.30
, pp. 806-819
-
-
Ritt, D.A.1
Monson, D.M.2
Specht, S.I.3
Morrison, D.K.4
-
119
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
-
120
-
-
79955472800
-
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
-
Brennan, D. F. et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366-369 (2011).
-
(2011)
Nature
, vol.472
, pp. 366-369
-
-
Brennan, D.F.1
-
121
-
-
79953784580
-
RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling
-
McKay, M. M., Ritt, D. A. & Morrison, D. K. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr. Biol. 21, 563-568 (2011).
-
(2011)
Curr. Biol
, vol.21
, pp. 563-568
-
-
McKay, M.M.1
Ritt, D.A.2
Morrison, D.K.3
-
122
-
-
79955044151
-
Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF
-
Hu, J. et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl Acad. Sci. USA 108, 6067-6072 (2011).
-
(2011)
Proc. Natl Acad. Sci. USA
, vol.108
, pp. 6067-6072
-
-
Hu, J.1
-
123
-
-
84862908097
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
-
Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 207-215
-
-
Su, F.1
-
124
-
-
84862908526
-
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
-
Oberholzer, P. A. et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321 (2012).
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 316-321
-
-
Oberholzer, P.A.1
-
125
-
-
84861417677
-
BRAF inhibition in refractory hairy-cell leukemia
-
Dietrich, S. et al. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012).
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 2038-2040
-
-
Dietrich, S.1
-
126
-
-
84866595717
-
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib
-
Gautschi, O. et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J. Thorac. Oncol. 7, e23-e24 (2012).
-
(2012)
J. Thorac. Oncol
, vol.7
-
-
Gautschi, O.1
-
127
-
-
78650391890
-
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
-
Comin-Anduix, B. et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin. Cancer Res. 16, 6040-6048 (2010).
-
(2010)
Clin. Cancer Res
, vol.16
, pp. 6040-6048
-
-
Comin-Anduix, B.1
-
128
-
-
77954373338
-
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
-
Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213-5219 (2010).
-
(2010)
Cancer Res
, vol.70
, pp. 5213-5219
-
-
Boni, A.1
-
129
-
-
4544367874
-
Technology platforms for pharmacogenomic diagnostic assays
-
DOI 10.1038/nrd1496
-
Koch, W. H. Technology platforms for pharmacogenomic diagnostic assays. Nature Rev. Drug Discov. 3, 749-761 (2004). (Pubitemid 39242827)
-
(2004)
Nature Reviews Drug Discovery
, vol.3
, Issue.9
, pp. 749-761
-
-
Koch, W.H.1
-
130
-
-
84857232726
-
Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma
-
Halait, H. et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn. Mol. Pathol. 21, 1-8 (2012).
-
(2012)
Diagn. Mol. Pathol
, vol.21
, pp. 1-8
-
-
Halait, H.1
-
131
-
-
72949090154
-
Cancer research. Melanoma drug vindicates targeted approach
-
Garber, K. Cancer research. Melanoma drug vindicates targeted approach. Science 326, 1619 (2009).
-
(2009)
Science
, vol.326
, pp. 1619
-
-
Garber, K.1
-
132
-
-
0026754369
-
Activation of the MAP kinase pathway by the protein kinase raf
-
Howe, L. R. et al. Activation of the MAP kinase pathway by the protein kinase raf. Cell 71, 335-342 (1992).
-
(1992)
Cell
, vol.71
, pp. 335-342
-
-
Howe, L.R.1
-
133
-
-
0025355689
-
Transactivation of c-fos and β-actin genes by raf as a step in early response to transmembrane signals
-
Jamal, S. & Ziff, E. Transactivation of c-fos and β-actin genes by raf as a step in early response to transmembrane signals. Nature 344, 463-466 (1990).
-
(1990)
Nature
, vol.344
, pp. 463-466
-
-
Jamal, S.1
Ziff, E.2
-
134
-
-
33947594129
-
Hyperactive Ras in developmental disorders and cancer
-
DOI 10.1038/nrc2109, PII NRC2109
-
Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nature Rev. Cancer 7, 295-308 (2007). (Pubitemid 46480970)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.4
, pp. 295-308
-
-
Schubbert, S.1
Shannon, K.2
Bollag, G.3
-
135
-
-
0027200883
-
Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro
-
DOI 10.1038/364352a0
-
Warne, P. H., Viciana, P. R. & Downward, J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364, 352-355 (1993). (Pubitemid 23265279)
-
(1993)
Nature
, vol.364
, Issue.6435
, pp. 352-355
-
-
Warne, P.H.1
Viciana, P.R.2
Downward, J.3
-
136
-
-
0028272507
-
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
-
DOI 10.1038/369411a0
-
Leevers, S. J., Paterson, H. F. & Marshall, C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411-414 (1994). (Pubitemid 24184056)
-
(1994)
Nature
, vol.369
, Issue.6479
, pp. 411-414
-
-
Leevers, S.J.1
Paterson, H.F.2
Marshall, C.J.3
-
137
-
-
0029811985
-
Oligomerization activates c-Raf-1 through a Ras-dependent mechanism
-
DOI 10.1038/383181a0
-
Luo, Z. et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383, 181-185 (1996). (Pubitemid 26303983)
-
(1996)
Nature
, vol.383
, Issue.6596
, pp. 181-185
-
-
Luo, Z.1
Tzivion, G.2
Belshaw, P.J.3
Vavvas, D.4
Marshall, M.5
Avruch, J.6
-
138
-
-
0035328521
-
Active ras induces heterodimerization of cRaf and BRaf
-
Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595-3598 (2001). (Pubitemid 32694968)
-
(2001)
Cancer Research
, vol.61
, Issue.9
, pp. 3595-3598
-
-
Weber, C.K.1
Slupsky, J.R.2
Andreas Kalmes, H.3
Rapp, U.R.4
|